FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Fast-Track for Adicet Systemic Sclerosis Drug

FDA grants fast-track designation for Adicet Bios ADT-001 to treat systemic sclerosis.

latest-news-card-1
Human Drugs

19-Page Exela Pharma Sciences FDA-483

FDA releases the 19-page form FDA-483 with 15 observations from an inspection at the Exela Pharma Sciences outsourcing facility in Lenoir, NC.

Human Drugs

FDA Clears Visby Respiratory Health Test

FDA clears a Visby Medical 510(k) for its point-of-care test for detecting respiratory infections caused by influenza A & B, and Covid-19.

latest-news-card-1
Human Drugs

7 Observations in Zhejiang Huahai FDA-483

FDA releases the form FDA-483 with seven observations from an inspection at Chinas Zhejiang Huahai API manufacturing facility.

latest-news-card-1
Human Drugs

6 Observations on Piramal Pharma FDA-483

FDA releases the form FDA-483 with six observations from an inspection at Indias Piramal Pharma API manufacturing facility.

latest-news-card-1
Human Drugs

Indoco Remedies FDA-483 Released

FDA releases the form FDA-483 with seven observations from an inspection at Indias Indoco Remedies manufacturing facility for sterile and non-sterile ...

latest-news-card-1
Human Drugs

Camizestrant in Breast Cancer Meets Primary Endpoint

Data from an AstraZeneca interim analysis of its SERENA-6 Phase 3 breast cancer trial show that camizestrant in combination with a cyclin-dependent ki...

latest-news-card-1
Human Drugs

Google Watch Cleared for Pulse Loss Detection

FDA clears a Google 510(k) for its Loss of Pulse Detection feature and its use on the Pixel Watch 3.

latest-news-card-1
Human Drugs

CDER Touts FY 2024 Drug Safety Activities

CDERs 10th yearly drug safety report highlights the FY 2024 establishment of two new units contributing to drug safety.

latest-news-card-1
Human Drugs

16% Oncology Phase 2 Patients Get Drugs Later OKd

Canadian researchers find that 16% of patients in Phase 2 oncology trials receive treatments that are later approved by FDA for their condition.